{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-127041","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2026-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.136309+00:00","generated_at":"2026-05-15T08:36:23.816790+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"GLOW2 Phase 3 positive: Zenkuda meets primary endpoint, 62.5% vs 3.3% DRSS improvement, BLA accelerated","bullets":["62.5% of Zenkuda patients achieved ≥2-step DRSS improvement vs 3.3% sham (p<0.0001).","85% risk reduction in sight-threatening complications (2.4% vs 15.8%, p=0.0001); 13.7% had ≥3-step DRSS improvement vs 0% sham.","Zenkuda well-tolerated: 0% intraocular inflammation, low cataract rate (2.3% vs 1.6%).","Efficacy independent of GLP-1 use: 60.0% with GLP-1 vs 64.3% without GLP-1.","Kodiak intends to accelerate BLA for Zenkuda; KSI-501 (wet AMD) readout 3Q2026, KSI-101 (MESI) 4Q2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-127041","json":"https://secwatch.observer/filing/0001193125-26-127041.json","markdown":"https://secwatch.observer/filing/0001193125-26-127041.md","text":"https://secwatch.observer/filing/0001193125-26-127041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/0001193125-26-127041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:36:23.816790+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}